Media coverage about Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Trillium Therapeutics earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.1786108507527 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the news stories that may have effected Accern’s scoring:

A number of analysts have recently commented on the stock. HC Wainwright set a $7.00 target price on shares of Trillium Therapeutics and gave the company a “buy” rating in a report on Monday, August 14th. Cowen and Company restated a “buy” rating on shares of Trillium Therapeutics in a report on Wednesday, July 5th. Finally, Zacks Investment Research upgraded shares of Trillium Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, September 19th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Trillium Therapeutics presently has a consensus rating of “Buy” and an average target price of $15.00.

Shares of Trillium Therapeutics (NASDAQ TRIL) traded down 5.48% during mid-day trading on Friday, hitting $6.05. 152,308 shares of the stock were exchanged. Trillium Therapeutics has a 12 month low of $4.15 and a 12 month high of $15.87. The firm’s market cap is $65.30 million. The stock’s 50 day moving average is $5.02 and its 200 day moving average is $5.17.

TRADEMARK VIOLATION WARNING: This news story was first published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.

Insider Buying and Selling by Quarter for Trillium Therapeutics (NASDAQ:TRIL)

Receive News & Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.